Fibrocell Science Inc (NASDAQ:FCSC) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Monday.
According to Zacks, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. “
Other equities analysts have also issued reports about the company. HC Wainwright set a $6.00 price target on Fibrocell Science and gave the stock a “buy” rating in a report on Wednesday, August 9th. ValuEngine raised Fibrocell Science from a “sell” rating to a “hold” rating in a report on Thursday, July 20th.
Shares of Fibrocell Science (NASDAQ FCSC) opened at 2.61 on Monday. The company’s market capitalization is $38.35 million. Fibrocell Science has a 52-week low of $1.57 and a 52-week high of $4.64. The stock’s 50 day moving average price is $3.56 and its 200-day moving average price is $2.29.
Fibrocell Science (NASDAQ:FCSC) last released its earnings results on Wednesday, August 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.31). Fibrocell Science had a negative return on equity of 293.07% and a negative net margin of 4,307.60%. On average, equities analysts expect that Fibrocell Science will post ($2.58) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Fibrocell Science Inc (FCSC) Stock Rating Lowered by Zacks Investment Research” was originally published by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://transcriptdaily.com/2017/08/16/fibrocell-science-inc-fcsc-stock-rating-lowered-by-zacks-investment-research.html.
Several institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC raised its position in Fibrocell Science by 272.4% in the fourth quarter. Renaissance Technologies LLC now owns 194,000 shares of the company’s stock worth $122,000 after buying an additional 141,900 shares during the last quarter. Parametric Portfolio Associates LLC raised its position in Fibrocell Science by 264.0% in the second quarter. Parametric Portfolio Associates LLC now owns 48,259 shares of the company’s stock worth $194,000 after buying an additional 35,000 shares during the last quarter. Finally, Creative Planning raised its position in Fibrocell Science by 395.3% in the second quarter. Creative Planning now owns 61,090 shares of the company’s stock worth $245,000 after buying an additional 48,755 shares during the last quarter. 55.31% of the stock is owned by hedge funds and other institutional investors.
About Fibrocell Science
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with MarketBeat.com's FREE daily email newsletter.